



▲ **Hormone therapy: A dangerous elixir?** Pearson, H. *Nature* 30 September (2004)



◀ **The price of hope.**

Chirac, P.

Nature

7 October (2004)

A review of the book *Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases* by Kremer, M. & Glennerster, R.

● **Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.**

Forman, M. S., Trojanowski, J. Q. & Lee, V. M.-Y.

Nature Medicine

October (2004)

This Historical Perspective is part of a series of articles that highlight some of the major biomedical achievements of the past decade.

● **The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies.**

Epstein, R. J.

Nature Reviews Cancer

November (2004)

This Perspective article discusses the mechanisms and potential advantages of dose-dense adjuvant breast cancer chemotherapy as a new treatment strategy for improving tumour control.

● **Exploiting anti-human immunodeficiency virus drugs for tumour therapy.**

Monini, P., Sgadari, C., Toschi, E.,

Barillari, G. & Ensoli, B.

Nature Reviews Cancer

November (2004)

Recent evidence indicates that antiretroviral agents that inhibit human immunodeficiency virus (HIV) protease have direct anti-angiogenic and antitumour effects, making them promising candidates for novel cancer therapies both in patients with and without HIV.

● **The prediction of disease risk in genomic medicine.**

Hall, W. D., Morley, K. I. &

Lucke, J. C.

EMBO Reports

October (2004)

● **Suppressing the self in rheumatoid arthritis.**

Mittler, R. S.

Nature Medicine

October (2004)

New work indicating that antibodies that stimulate T-cell co-stimulatory receptors are successful at blocking the progression of rheumatoid arthritis in a mouse model is highlighted in this News and Views article.

● **Turning aptamers into anticoagulants.**

Famulok, M.

Nature Biotechnology

November (2004)

▼ **Focus on biomanufacturing and bioprocessing**

Nature Biotechnology

November (2004)

Articles include:

● **Biomanufacturing, from bust to boom ... to bubble?**

Thiel, K. A.

● **Biogenerics standoff.**

Herrera, S.

